Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Benzocaine · 1 trial · 1 indication
A timer is started upon the intake of a single dose and stopped when the subject considers he/she has experienced meaningful pain relief.
| Arm | Type | Description |
|---|---|---|
| Benzocaine 8 mg | EXPERIMENTAL | Benzocaine 8 mg, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days. |
| Placebo | PLACEBO_COMPARATOR | Placebo, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days. |
| Name | Type | Description |
|---|---|---|
| Benzocaine 8 mg | DRUG | Benzocaine 8 mg, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days. |
| Placebo | DRUG | Placebo, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days. |
Subject Inclusion Criteria Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study: 1. Subjects of 18 years of age or older, suffering from throat pain caused by acute upper respiratory tract infection; 2. Symptoms of acute throat pain have been pers...
Benzocaine is a small molecule being developed for the treatment of sore throat. It is administered as a lozenge and is intended to provide relief from the discomfort associated with this condition. The drug is currently in Phase 3 clinical development.
Benzocaine is being developed by Johnson & Johnson, a company traded on the stock exchange under the ticker symbol JNJ. The company is conducting clinical trials to evaluate the efficacy and safety of this drug for the treatment of sore throat.
Benzocaine is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 3 trial for this drug has been completed, and it is being studied for the treatment of sore throat.
Benzocaine has one completed Phase 3 clinical trial, identified by the NCT number NCT03432923. This trial was a randomized, double-blind, placebo-controlled study that enrolled 260 participants to evaluate the efficacy and safety of a Benzocaine lozenge for the treatment of sore throat.
Benzocaine is not FDA approved for the treatment of sore throat. It is an investigational drug currently in Phase 3 clinical development. The completed clinical trial for this drug was conducted in Russia, and further regulatory review would be required before it could be considered for approval.